A Hoosier Cancer Research Network trial, HCRN-LUN18-357, titled “P1.08D.03 Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC)” has been accepted as a poster presentation and will be presented at the World Conference on Lung Cancer Meeting on September 8, 2024 from 12:00 pm-2:00 pm.

Congratulations to all co-authors and study teams involved in the study!

Led by Rachel Sanborn, MD, of Providence, this study explored whether adding a single dose of durvalumab before concurrent chemoradiation, followed by consolidation durvalumab, could improve outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC). The standard of care, based on the PACIFIC trial, shows a 12-month progression-free survival (PFS) of 55.9%. This study aimed to see if the addition of induction durvalumab could further enhance 12-month PFS compared to this historical benchmark.

The trial was designed as a single-arm study, enrolling 10 patients for a safety run-in before expanding to 54 patients. However, due to the pandemic, enrollment was halted after the initial 10 patients. The treatment protocol included one dose of induction durvalumab, followed by concurrent chemoradiation and consolidation durvalumab for up to 12 cycles. The primary goals were to assess 12-month PFS, safety, and feasibility, with exploratory objectives like objective response rate (ORR) and outcomes based on PD-L1 and tumor mutational burden (TMB) status.

Learn more about this study: https://clinicaltrials.gov/study/NCT04364048

View session information: https://cattendee.abstractsonline.com/meeting/20598/Session/271